Nicolas Béry

Advances in targeted degradation of endogenous proteins

De novo design of allosterically switchable protein assemblies

Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective

Cysteine-based regulation of redox-sensitive Ras small GTPases

RAS-targeted therapies: is the undruggable drugged?

Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites

Engineered protein scaffolds as leads for synthetic inhibitors of protein–protein interactions

Oxidative Stress in Cancer

PROTAC targeted protein degraders: the past is prologue

The current understanding of KRAS protein structure and dynamics

Targeted Protein Degradation Tools: Overview and Future Perspectives

Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States

Protein Ensemble Generation Through Variational Autoencoder Latent Space Sampling

COMBINES-CID: An Efficient Method for De Novo Engineering of Highly Specific Chemically Induced Protein Dimerization Systems

Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective toward the Cellular RHOB GTP-Bound Conformation

KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe

Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies

BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions